Greenwich LifeSciences Stock Jumps 7% on 10-K Update and 70-80% Efficacy
GLSI•Greenwich LifeSciences reported its delayed fiscal 2025 Form 10-K is in final audit stages, easing Nasdaq compliance overhang and fueling a 7% pre-market share rally. The biotech holds an unaudited $10.5 million cash balance and has screened over 1,300 patients in its Flamingo-01 breast cancer trial showing 70–80% recurrence reduction.
1. Filing Delay and Nasdaq Overhang
Greenwich LifeSciences said its fiscal 2025 Form 10-K filing is in the final stages of audit following coordination between current and former auditors. The update addresses accounts payable adjustments tied to increased patient screening and helps satisfy Nasdaq’s delayed filing notices, leading to a 7% pre-market share increase.
2. Cash Position and Financial Impact
As of March 31, 2026, the company reported an unaudited cash balance of approximately $10.5 million. Management emphasized that recent accounting adjustments are immaterial and the cash position remains sufficient to support ongoing operations and trial activities.
3. Flamingo-01 Trial Progress and Early Data
The biotech is conducting the Flamingo-01 Phase III trial for GLSI-100 breast cancer therapy, with over 1,300 patients screened to date. Preliminary data indicate a 70% to 80% reduction in cancer recurrence after six doses and significant immune response increases among participants.
